STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] Enovis CORP Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Enovis director Angela S. Lalor reported acquiring 742 shares of Enovis Corp (ENOV) on 09/30/2025 at a reported price of $0.00, increasing her direct beneficial ownership to 21,295 shares. The Form 4 shows the filing was signed by attorney-in-fact Brian P. Hanigan on 10/01/2025. The filing identifies Lalor as a director and indicates this is a single-person Form 4 filing. No derivative transactions or additional details are reported.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: A director reported a small non-derivative share acquisition, increasing direct holdings to 21,295 shares; transaction appears routine and non-material.

The Form 4 documents a 09/30/2025 acquisition of 742 common shares by director Angela S. Lalor at a reported price of $0.00, with total direct beneficial ownership of 21,295 shares following the transaction. There are no derivative securities reported and no price or value context beyond the $0.00 price field. For most investors this level of share movement by a director in isolation is unlikely to be material relative to company market capitalization, and the filing contains no additional corporate or compensatory detail.

TL;DR: Routine insider disclosure showing a director-level acquisition; disclosure compliance appears met, with no governance red flags in the filing.

The filing identifies Lalor as a director and reports the acquisition clearly on the Form 4, signed by an attorney-in-fact on 10/01/2025. The absence of derivative transactions and the straightforward reporting of beneficial ownership increases suggest standard compliance with Section 16 filing requirements. The $0.00 price field is noted as reported; the form does not provide explanatory text about transaction consideration.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Lalor Angela S

(Last) (First) (Middle)
2711 CENTERVILLE ROAD
SUITE 400

(Street)
WILMINGTON DE 19808

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Enovis CORP [ ENOV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock, par value $0.001 09/30/2025 A 742 A $0.00 21,295 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Brian P. Hanigan, attorney-in-fact 10/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Enovis Corp

NYSE:ENOV

ENOV Rankings

ENOV Latest News

ENOV Latest SEC Filings

ENOV Stock Data

1.53B
56.28M
1.57%
121.34%
12.07%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
WILMINGTON